NEW YORK, NY--(Marketwire - Oct 13, 2011) - TheraBiogen, Inc. (OTCBB: [ TRAB ]), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, today announced that it has recently begun shipment of orders totaling $1,057,000 of Thera Max™ Cold and Flu Relief to stores nationwide for the fall flu season.

These shipments include a record number of reorders. Combined with an order of $263,000 previously reported, the Company has booked over $1,320,000 since August.

Mr. Kelly Hickel, CEO of TheraBiogen, commented, "We are proud to announce these record orders of our Thera Max™ Cold and Flu product." He continued, "This more than doubles the amount of product that we shipped last year at this time and the reorders cover over 16 distribution centers around the country, further validating our belief in the effectiveness of our product line."

Thera Max^™ is available for purchase in over twelve thousand locations from Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and others. For more information on Thera Max^™ visit our website [ www.theramaxrelief.com ] or our Facebook page at facebook.com/theramaxnasalspray.

About TheraBiogen, Inc.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other products on the market. For further information please visit [ www.theramaxrelief.com ].

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.